期刊文献+

乳腺癌化疗前后表皮生长因子受体表达的变化及其意义

下载PDF
导出
摘要 目的探讨乳腺癌患者表皮生长因子受体在P-gp底物化疗药短期化疗前后蛋白表达的变化及意义。方法采用免疫组织化学方法,分别对24例乳腺癌组织标本进行短期化疗前后EGFR、C-erbB-2、CD147及Ki67的表达进行评估。结果化疗后,EGFR表达比化疗前明显增加,C-erbB-2、CD147和Ki67表达则明显下降,但只有Ki67有统计学意义。结论短期化疗即可杀伤肿瘤细胞,也可诱导EGFR表达增强,使Ki67增生减弱,但不足以引起肿瘤细胞的转移。即并不引起CD147等下游因子的表达。
作者 叶丽君
出处 《中国医药指南》 2012年第18期154-155,共2页 Guide of China Medicine
  • 相关文献

参考文献4

  • 1Saeki T, Tauruo T, Sato W, et al.Drug resistance in chemotherapy for breast cancer[J].Cancer Chem other Pharmacol,2005,56(1): 84-89.
  • 2Hoffmann J,Schmidt PP, Hansch W, et al.Anticancer drug sensitivi- ty and expression of multi-drug resistance markers in early passa- ge human sarcomas[J].Clin Cancer Res, 1999,5(8): 2198-2204.
  • 3李哲,袁守军.表皮生长因子受体酪氨酸激酶抑制剂在肿瘤治疗中的应用[J].中国临床药理学与治疗学,2004,9(4):361-364. 被引量:14
  • 4Toi M.Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer[J]. Cancer,1990,65(9): 1980.

二级参考文献22

  • 1[1]Kathryn SK, Brian JD. Protein tyrosine kinases and cancer[ J].Biochimica Biophysica Acta, 1997; 1333(3) :217 - 48
  • 2[2]Fortunato C, Giampaolo T. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor[J]. Clin Cancer Res, 2001 ;7(10) :2958 - 70
  • 3[3]Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Basellga J, et al. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor trceptor activation and inhibits growth of cancer cells in a receptor number- dependent manner[J]. Clin Cancer Res, 1997;3(11) :2099 - 106
  • 4[4]Woodburn JR, Barker AJ. 4-Anilinoquii-nazolines-a potential new therapy for major human solid tumors overexpressing the EGF receptor[J]. Br J Cancer, 1996;74(1) :18 - 24
  • 5[5]Di GE, Barbarino M, Bruzzese F, De Lorenzo S, Caraglia M,Abbruzzese A, et al. Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiprolfferative effect of ZD1839 (‘ Iressa' ), an epidermal growth factor receptor tyrsine kinase inhibitor, in head and neck squamous carcinoma cells [ J]. J Cell Physiol, 2003;195(1):139-50
  • 6[6]Ciardiello F, Caputo R, Bianco R, Damianco V, Pomatico G,De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa),an epidermal growth factor receptor-sensitive tyrosine kinase inhibitor[J]. Clin Cancer Res,2000;6(5) :2053 - 63
  • 7[7]Solomon B, Hagekyriakou J, Trivett MK, Stacker SA,McArthur GA, Cullinane C. EGFR blockade with ZD1839(" Iressa") potentiates the antitumor effects of single and multiple fractions of ionzing radiation in human A431 squamous cell carcinoma, Epidermal growth factor receptor[J]. Int J Radiat Oncol Biol Phys, 2003; 55 (3): 713 - 23
  • 8[8]Baselga J, Rischin D, Ranson M, Calvert H, Raymond E,Kieback DG, et al. Phase Ⅰ safety, pharmacokinetic, and pharmacodlynamic trial of ZD1839, a selective oral epidemal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types[J]. J Clin Oncol,2002;20(21 ):4292 - 302
  • 9[9]Miller VA, Johnson D, Heelan RT, Pizzo BA, Perez WJ, Bass A, et al. A pilot trial demonstrates the safety of ZD1839 (Iressa), an oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in combination with carboplatin (C) and paclitaxcl (P) in previously untreated advanced nor-small lurg cancer (NSLC)[J]. Proo c Soc Clin Oncol,2001 ;21:326
  • 10[10]Perter T, Guido B, Elisaleth B, Giorgio C, Pascal F, Paul M,et al. Tyrosine Kinase Inhibitors:From Rational Design to Clinical Trials[J]. Med Res Rev,2001 ;21(6) :499 - 512

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部